Programs

Mucosis’s lead program SynGEM® seeks to develop a new mucosal vaccines to prevent respiratory syncytial virus vaccine that can be administered to humans by a simple spray in the nose. The program is particularly directed at achieving better protection against RSV in vulnerable people, such as elderly and children. Mucosis also runs research programs aimed at the development of mucosal vaccines to prevent pneumococcal related diseases, and an oral vaccine to prevent bacterial diarrhea (shigella/etec).  These programs build upon the success of the Mucosis FluGEM® which achieved proof-of-concept for the Mimopath platform.

The development phases of the Mucosis programs

research programs

10.11.14 Mucosis Presents Data on Intranasal Respiratory Syncytial Virus Vaccine SynGEM® at RSV2014 Symposium
more >

20.10.14 Mucosis Presents Data on Intranasal RSV Vaccine SynGEM® at Vaccines 2014 Conference
more >

30.09.14 Mucosis Presents Infectious Diseases Vaccines Pipeline Update at SACHs Associates 14th Annual Biotech in Europe Forum
more >

22.05.14 Mucosis receives financial support from the Dutch government for its SynGEM® program
more >

15.04.14 Mucosis announces a strategic partnership with Changchun BCHT Biotechnology of China and raises additional capital
more >

12.08.13 Mucosis announces publication of data demonstrating safety and protection by mucosally administered Mimopath®-based prefusion-like F RSV vaccines
more >